Biocon plans to introduce generic versions of the weight-loss drug Wegovy in India and Canada by 2027, according to CEO Siddharth Mittal.

Stock Market Today: Indian equities rebounded strongly on Tuesday, 15 July, snapping a four-day losing streak as broad-based ...

M&M, Wipro, Tech Mahindra, Nestle, SBI and Infosys led the gainers of Nifty 50 pack. Lack of fresh triggers, mixed global ...

Biocon plans to launch generic copies of Wegovy in India and Canada within two years, targeting a growing drug market ...

Biocon is set to launch generic versions of Wegovy in India and Canada, aiming for market entry by late 2026 or early 2027.

India's pharma and healthcare sector saw 57 deals worth $1.30 billion in the quarter ending June. This reflects a drop ...

Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years, a top executive told Reuters ...

Nifty rose above 25,100 and Sensex gained 76 points, recovering from earlier losses led by sectoral strength.Stock-Specific ...

Kiran Mazumdar-Shaw assessed the readiness of the Hebbagodi Metro Station with BMRCL officials, expressing enthusiasm for the ...

The US Food and Drug Administration approved, the first rapid-acting interchangeable biosimilar product, Kirsty (insulin ...

Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years ...

Mutual funds pumped Rs 154 billion into Indian equities in June 2025, signalling strong market confidence. Top buys included Asian Paints, Infosys, Trent, Dixon Technologies, and Kaynes Technology.